EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Dr. Ken K. Ren as interim CEO, effective April 2, 2012.
Ren has distinguished himself through roles in drug discovery, development and regulation, and brings years of experience in conducting global trials for multi-national pharmaceutical and biotech companies. He was also the founder and key manager of several private companies operating in the U.S. and China in pharmaceutical development and services.
The EntreMed board of directors has approved the issuance of an inducement option award to Ren to purchase up to 150,000 shares of the company's common stock. The option will have a term of 10 years.